{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:47:29Z","timestamp":1775890049651,"version":"3.50.1"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We evaluated trends in\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            antimicrobial susceptibility in U.S. hospitals in the 2010\u20132016 period. A total of 21,056 clinical isolates from 42 medical centers were tested for susceptibility by broth microdilution methods. Methicillin-resistant\n            <jats:named-content content-type=\"genus-species\">S. aureus<\/jats:named-content>\n            (MRSA) rates decreased from 50.0% (in 2010) to 42.2% (in 2016). Susceptibility to erythromycin, levofloxacin, and clindamycin increased slightly, whereas susceptibility to ceftaroline, trimethoprim-sulfamethoxazole, and tetracycline remained stable. Ceftaroline retained potent activity against methicillin-susceptible\n            <jats:named-content content-type=\"genus-species\">S. aureus<\/jats:named-content>\n            (MSSA) and MRSA (97.2% susceptible) with no marked variations.\n          <\/jats:p>","DOI":"10.1128\/aac.01043-17","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T00:30:28Z","timestamp":1497918628000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":34,"title":["Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016"],"prefix":"10.1128","volume":"61","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Streit","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.174"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2200"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00081-09"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw444"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0075-6"},{"key":"e_1_3_2_7_2","volume-title":"Teflaro package insert","author":"Allergan","year":"2016","unstructured":"Allergan. 2016. Teflaro package insert. Allergan, Parsippany, NJ. http:\/\/www.allergan.com\/assets\/pdf\/teflaro_pi."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00484-13"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000307"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.01.015"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2015.209"},{"key":"e_1_3_2_12_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201410th ed","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201410th ed. CLSI M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_13_2","volume-title":"CLSI M100-S27","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing: 27th informational supplement. CLSI M100-S27. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_14_2","unstructured":"EUCAST. 2017. Breakpoint tables for interpretation of MICs and zone diameters version 7.0 2017. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_7.0_Breakpoint_Tables.pdf\n."},{"key":"e_1_3_2_15_2","volume-title":"Tygacil package insert","author":"Wyeth Pharmaceuticals","year":"2016","unstructured":"Wyeth Pharmaceuticals. 2016. Tygacil package insert. Wyeth Pharmaceuticals, Philadelphia, PA. http:\/\/www.tygacil.com."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.8.593"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq067"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01384-09"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-4-200802190-00204"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/528716"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2013.02.007"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu410"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01043-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01043-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:55:28Z","timestamp":1645476928000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01043-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1128\/AAC.01043-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01043-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"2017-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01043-17"}}